1
Norihito Ohi, Nobuaki Sato, Motohiro Soejima, Takashi Doko, Taro Terauchi, Yoshimitsu Naoe, Takafumi Motoki: Pyrazole compound and medicinal composition containing the same. Eisai R & D Management, Birch Stewart Kolasch & Birch, September 30, 2008: US07429609 (53 worldwide citation)

The present invention provides a novel compound having an excellent JNK inhibitory effect. That is, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein R1 designates —(CO)h—(NRa)j—(CRb═CRc)k—Ar (wherein Ra, Rb and Rc each independently designate ...


2
Hitoshi Harada, Masato Ueda, Yoshihiko Kotake, Masahiro Yasuda, Daisuke Iida, Junichi Nagakawa, Makoto Nakagawa: Pyrimidine compound and medicinal composition thereof. Eisai R&D Management, Birch Stewart Kolasch & Birch, July 8, 2008: US07396836 (50 worldwide citation)

A compound having excellent adenosine receptor (A1, A2A, A2B receptor) antagonistic action, of the following formula, a salt thereof or a solvate of them: wherein, R1 and R2, same or different, each represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a ...


3
MOTOKI TAKAFUMI: Spiroaminodihydrothiazine derivatives. EISAI R&D MANAGEMENT, Asamura Kiyoshi, February 4, 2010: WO/2010/013794 (48 worldwide citation)

A compound represented by the general formula (I): or a pharmaceutically acceptable salt thereof, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer- type deme ...


4
MOTOKI TAKAFUMI: スピロアミノジヒドロチアジン誘導体 (JA), Spiroaminodihydrothiazine derivative (EN). EISAI R & D MANAGEMENT, Asamura Kiyoshi Et Al, February 4, 2010: WO/2010/013302 (46 worldwide citation)

A compound represented by the general formula (I) [wherein ring A is C6-10 aryl, etc.; L is a single bond, a group represented by the formula -C(=O)NRL- (RL is hydrogen or C1-6 alkyl optionally having one to three substituents selected from a substituent group (α)), etc.; ring B is C6-10 aryl, etc.; ...


5
Suzuki Yuichi, Motoki Takafumi, Kaneko Toshihiko, Takaishi Mamoru, Ishida Tasuku, Takeda Kunitoshi, Kita Yoichi, Yamamoto Noboru, Khan Afzal, Dimopoulos Paschalis: (Ja) 縮合アミノジヒドロチアジン誘導体, (En) Condensed aminodihydrothiazine derivative. Eisai R & D Management, Suzuki Yuichi, Motoki Takafumi, Kaneko Toshihiko, Takaishi Mamoru, Ishida Tasuku, Takeda Kunitoshi, Kita Yoichi, Yamamoto Noboru, Khan Afzal, Dimopoulos Paschalis, ASAMURA Kiyoshi, July 23, 2009: WO/2009/091016 (40 worldwide citation)

(EN) Disclosed is a compound represented by General formula (I), a pharmaceutically acceptable salt thereof, or a solvate of the compound or the pharmaceutically acceptable salt, which has an inhibitory activity of the production of Aβ or a BACE1-inhibiting activity, and is therefore useful as a pro ...


6
ELLARD JOHN MARK: Fused aminodihydro-oxazine derivatives. EISAI R&D MANAGEMENT, Crooks Elizabeth Caroline, January 27, 2011: WO/2011/009898 (37 worldwide citation)

A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is -NReCO- or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene ...


7
Kimura Teiji, Kawano Koki, Doi Eriko, Kitazawa Noritaka, Shin Kogyoku, Miyagawa Takehiko, Kaneko Toshihiko, Ito Koichi, Takaishi Mamoru, Sasaki Takeo, Hagiwara Hiroaki: (Ja) シンナミド化合物, (En) Cinnamide compound. Eisai R & D Management, Kimura Teiji, Kawano Koki, Doi Eriko, Kitazawa Noritaka, Shin Kogyoku, Miyagawa Takehiko, Kaneko Toshihiko, Ito Koichi, Takaishi Mamoru, Sasaki Takeo, Hagiwara Hiroaki, ASAMURA Kiyoshi, December 8, 2005: WO/2005/115990 (36 worldwide citation)

(EN) A compound represented by the formula (I): (wherein Ar1 represents imidazolyl optionally substituted by one to three substituents; Ar2 represents a pyridinyl, pyrimidinyl, or phenyl group optionally substituted by one to three substituents; X1 represents (1)-C≡C- or (2) an optionally substitute ...


8
CASTRO PINEIRO JOSE LUIS: Fused aminodihydropyrimidone derivatives. EISAI R&D MANAGEMENT, Crooks Elizabeth Caroline, January 27, 2011: WO/2011/009897 (32 worldwide citation)

A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is -NReCO- or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene ...


9
Yuichi Suzuki, Takafumi Motoki, Toshihiko Kaneko, Mamoru Takaishi, Tasuku Ishida, Kunitoshi Takeda, Yoichi Kita, Noboru Yamamoto, Afzal Khan, Paschalis Dimopoulos: Fused aminodihydrothiazine derivatives. Eisai R&D Management, Fish & Richardson P C, April 17, 2012: US08158620 (31 worldwide citation)

A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene gr ...


10
Kimura Teiji, Kitazawa Noritaka, Kaneko Toshihiko, Sato Nobuaki, Kawano Koki, Ito Koichi, Doi Eriko, Takaishi Mamoru, Sasaki Takeo, Doko Takashi, Miyagawa Takehiko, Hagiwara Hiroaki: (Ja) 多環式シンナミド誘導体, (En) Polycyclic cinnamide derivative. Eisai R & D Management, Kimura Teiji, Kitazawa Noritaka, Kaneko Toshihiko, Sato Nobuaki, Kawano Koki, Ito Koichi, Doi Eriko, Takaishi Mamoru, Sasaki Takeo, Doko Takashi, Miyagawa Takehiko, Hagiwara Hiroaki, ASAMURA Kiyoshi, September 13, 2007: WO/2007/102580 (31 worldwide citation)

(EN) Disclosed is a compound represented by the formula (I) or a pharmacologically acceptable salt thereof: (I) wherein Ar1 represents an imidazolyl group which may be substituted by a C1-6 alkyl group, or the like; Ar2 represents a phenyl group which may be substituted by a C1-6 alkoxy group, or th ...